Introduction. D Sandhu 1, E Curless 2, J Dean 3, G Hackett 4, S Liu 5, D Savage 6, R Oakes 7 * and G Frentz 8
|
|
- Randolf Farmer
- 6 years ago
- Views:
Transcription
1 International Journal of Impotence Research (1999) 11, 91±97 ß 1999 Stockton Press All rights reserved /99 $ A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction D Sandhu 1, E Curless 2, J Dean 3, G Hackett 4, S Liu 5, D Savage 6, R Oakes 7 * and G Frentz 8 1 Department of Urology, Leicester General Hospital, Leicester, UK; 2 Centre, Bolton General Hospital, Bolton, UK; 3 Derriford Hospital, Plymouth, UK; 4 Good Hope Hospital, Sutton Cold eld, UK; 5 Department of Urology, City General Hospital, Stoke on Trent, UK; 6 St Vincents Medical Centre, Doncaster, UK; 7 Senetek plc, Kettering, Northamptonshire, UK; and 8 Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana, USA Three hundred and four patients with non-psychogenic erectile dysfunction (ED) completed a dose assessment phase with intracavernosal injection utilizing 25 mg vasoactive intestinal polypeptide (VIP) combined with phentolamine mesylate 1.0 mg (VIP=P-1) or 2.0 mg (VIP=P-2) in an autoinjector for a response rate of 83.9%. In a sub-group of 183 patients who withdrew from one or more previous ED therapies, 82% responded with an erection suitable for intercourse. One hundred and ninety- ve patients were subsequently treated in a placebo controlled phase. 75.1% responded to VIP=P-1, 12% to placebo (P < 0.001); 66.5% responded to VIP=P-2, 10.3% to placebo (P<0.001), with the median duration of erection of 54 min. The principal adverse event was transient facial ushing in 2770 injections (33.9%). There was no pain post injection and two episodes of priapism (0.05%). Only nine patients withdrew because of adverse events. Over 85% and 95% of patients were satis ed with the drug and auto-injector, respectively. Over 81% of patients and 76% of partners reported an improved quality of life. Keywords: vasoactive intestinal polypeptide; phentolamine; erectile dysfunction; intracavernous injection Introduction Vasoactive intestinal peptide (VIP), or aviptadil, is a 28 amino acid endogenous peptide widely distributed throughout the human body. VIP concentrations in cavernous blood increases up to 20-fold during erection 1 and its presence has been noted to be decreased in the penises of impotent men. 2,3 VIP belongs to the family of nonadrenergic, noncholinergic ancillary neurotransmitters which act by activation of cyclic-adenosine monophosphate (camp). 4 In addition, VIP may act with nitric oxide (NO) as a co-mediator of erection. 5 Its action results in the relaxation of cavernous smooth muscle and a possible effect on the veno-occlusive mechanism. In early studies, intra-cavernosal (IC) injection of VIP produced resulted in varying degrees of tumescence following vibratory and=or visual stimulation. 1,6,7 *Correspondence: Dr R Oakes, Senetek plc, 1400 Montague Court, Kettering Venture Park, Kettering, Northamptonshire, NN15 6XR UK. Received 15 June 1998; accepted 2 November 1998 When combined with the vasodilator phentolamine, Gerstenberg et al 8 reported encouraging results in 1380 IC injections in 52 patients with primarily nonpsychogenic impotence utilizing a dose range of 0.5 ± 2.0 mg phentolamine and 30 mg VIP. All patients achieved a satisfactory erection following sexual stimulation and there were minimal sideeffects, notably no priapism or post-injection pain. The drop out rate of 17% was low compared to that of 24 ± 42% reported in other studies. 9 In a recent study of 20 males with erectile dysfunction (ED), McMahon 10 reported encouraging results utilizing IC injection of 30 mg VIP combined with 1.0 or 2.0 mg phentolamine. An erection suf cient for penetration was achieved in all six patients with psychogenic, 7 out of 9 with arteriogenic, 2 out of 2 with neurogenic, and 1 out of 3 with venous leakage aetiologies, for an overall ef cacy of 80%. There was no priapism, 10% of patients complained of injection pain and 15% noted transient facial ushing. These ndings led to further evaluation of the VIP=Phentolamine combination (INVICORP TM ) for the treatment of ED utilizing IC injection. A novel auto-injector was developed for use with VIP=Phen-
2 92 tolamine (VIP=P). `Injection anxiety' is reduced and in a pilot study of 20 patients previously treated with IC self-injection utilizing VIP=P ampoules, the auto-injector was well received and the injection was described as `painless'. 11 We hereby report the results of a prospective, double-blind, cross-over, placebo controlled trial of the IC use of VIP=P utilizing a novel auto-injector for the treatment of predominantly non-psychogenic ED in 304 men. Methods Patient Selection Three hundred and four men with ED of at least one year duration were evaluated at 10 investigational sites within the United Kingdom. To be included in the study, men were required to be 18 y or older and currently be in a stable heterosexual relationship. Men were excluded from the study if their history suggested overt psychogenic aetiology, ability to perform occasional sexual intercourse without medication or physical aid, hypoactive sexual disorder, nocturnal or early morning erections, or if erection occurred in response to placebo during the training program. In addition speci c exclusion criteria included any known systemic disease which produces an overall weakness (for example, cancer, acquired immune de ciency syndrome), sickle cell trait or disease, hormonal imbalance requiring treatment (except diabetes mellitus (DM)), angina pectoris, uncompensated congestive heart failure, a history of alcohol or drug abuse, current infection of the genitourinary tract, indwelling urethral catheter, surgery which may prevent erectile response to medication, concurrent therapy which in the opinion of the investigator could seriously diminish the effect of study medication (for example, benzodiazipines, sedatives, stimulants, anti- or pro-adrenergic compounds), markedly abnormal ECG, biochemical or haematological results, and participation in any clinical study within the previous 30 d. All patients and their partners gave informed consent and the study was performed in accordance with the Declaration of Helsinki (revised version of Tokyo 1975, Venice 1983 and Hong Kong 1989) as well as the European Directive 91=507=EEC and CPMP Guidelines II.=3976=88-EN dated 11 July The study was approved by the Local Ethics Committee at each of the ten investigative sites. Study Design The study was conducted between January 1996 and December 1997, and was divided into a Dose Assessment Phase and two Placebo Controlled Phases, each of six month duration. In the Dose Assessment Phase 304 men who met the entry criteria were administered VIP=P-1 (25 mg VIP and 1.0 mg phentolamine in 0.35 ml) in the clinic by the investigator utilizing the auto-injector. Patients were as relaxed as possible and provided with suf cient privacy and visual stimulating material as required. A Grade 3 erection achieved in response to this test dose allowed the patient to be immediately admitted to the Placebo Controlled Phase. For purposes of this study, the grade of erection was scored as: 0ˆno effect; 1ˆtumescence only; 2ˆpartial erection, unsuitable for vaginal penetration; and 3ˆerection suitable for vaginal penetration (as judged in clinic) or sexual intercourse in home environment. Following this initial injection, patients underwent a period of training with placebo (0.35 ml) lled auto-injectors and required demonstration of adeptness in self-administration prior to home use. Patients who failed to respond adequately to in clinic VIP=P-1 were given two active auto-injectors for self-administration at home. The rst contained VIP=P-1 and the second VIP=P-2 (25 mg VIP and 2.0 mg phentolamine in 0.35 ml). Patients were instructed to keep a diary and report any response to the injection and any adverse events. Patients who achieved a grade three erection to in home VIP=P-1 were told to immediately notify their investigator and were allowed to enter the Placebo Controlled Phase, and the unused VIP=P-2 autoinjector was returned. Patients who did not achieve a satisfactory response to VIP=P-1 were told to administer the VIP=P-2 dose after a minimum 36 h waiting period. Patients who achieved a grade three erection with VIP=P-2 were allowed to enter the Placebo Controlled Phase; any other response was considered a treatment failure, entered into the study data and analyzed, the patient being withdrawn from the study. The pre- lled auto-injector utilized exclusively in this study was supplied by Senetek plc. This singleuse, disposable device is small ( ) and utilizes an ultra ne 29 gauge needle that is not visible to the patient prior to injection. The device delivers 0.35 ml in <5 s, the injection beginning only after the needle depth of 1.0 cm is achieved. Upon entering the Placebo Controlled Phase, patients were assigned consecutive numbers. Medication was supplied to the investigator in cartons labeled with each patient's unique identi cation number. Each carton contained two packages of six auto-injectors, each of which was randomized to include one placebo and ve active, the dose determined by the investigator and based upon the patient's response in the Dose Assessment Phase. Medication was dispensed to the patient in packages of six auto-injectors with instructions to use the auto-injectors in the exact numbered order, not to use any auto-injector within 36 h of previous use, and not to inject more often than three times in a
3 week. The response to each numbered injection, its duration and any adverse event was recorded by the patient in a diary. Following the twelfth injection, or after six months, all patients were seen by the local investigator, who reviewed diary entries, performed a complete physical examination, biochemical and haematology testing and ECG, following which the second package of twelve auto-injectors was dispensed. The examinations were repeated after using the second set of auto-injectors. On completion of the rst 12 injections (Placebo Controlled Phase I), a dose assessment was made by the patient and the investigator, and if necessary the dose adjusted prior to entry into the Placebo Controlled Phase II, which in all other respects was identical to the rst phase. For a patient to have completed each phase of the study, a minimum of nine injections and corresponding diary completions was required within each six month period. Overall results were assessed with a follow-up questionnaire completed by the patient and their partner. Adverse events were reported for each injection for which there was a corresponding diary entry. Results Dose assessment phase Table 1 Results of dose assessment phase Cumulative response rate (%) Characteristic VIP=P-1 VIP=P-2 AgeÐPatient (y) Mean 58.5 Range 27 ± 79 Aetiology of ED n Arteriogenic % 80.6% Diabetes mellitus % 85.5% Neurogenic % Mixed % 82.9% Total % 83.1% Previous therapy a (Agents) IC Alprostadil % 81.1% IC Papaverine= % 82.2% phentolamine Other (Yohimbine, % 84.4% vacuum devices) Total % 82.0% (Withdrawal Reason) Poor ef cacy % 73.2% Poor tolerability % 84.4% Poor acceptability % 94.4% Other % 91.3% Total % 82.6% a Patients may have been previously treated with more than one therapy. Patients may have recorded therapy but not always the reason for withdrawal. 93 During the dose assessment phase 255 out of 304 men had a grade three erection for an overall response rate of 83.9% with either of the two doses. Prior to commencing the Placebo Controlled Phase, 15 responders withdrew, seven for adverse events and eight for the following miscellaneous reasons: namely, four lost to follow-up, one had spontaneous resolution, and three had withdrawn consent. Patient demographics and response rate by aetiology for the remaining 289 patients is shown in Table 1, with the overall cumulative response being 83.0%. The total response by aetiologic category was calculated by the summation of responses from each successive injection, patients receiving three injections without obtaining a Grade 3 erection being considered non-responders. The lapse from time of injection to onset of tumescence was: 0 ± 5 min (41%), 5 ± 10 min (27%), 10 ± 20 min (14%), and 20 ± 30 min (2%) with 15% not having been recorded. During this phase, it was also noted that 82% of patients who withdrew from previous therapies and 73.2% who withdrew for the reason of poor ef cacy, responded to VIP=P-1 or VIP=P-2. (See Table 1) Placebo-controlled phase Two hundred and forty patients were enrolled into Placebo Controlled Phase I with the following aetiologies: arteriogenic (58), DM (53), Neurogenic (3) and Mixed (126). Forty- ve of these patients never used a single injector and were withdrawn as non protocol compliant. 172 out of 195 (88.2%) patients received at least one injection of active and placebo and could be analyzed under intention to treat, 133 (68.2%) met full Phase I protocol completion criteria. Reasons for withdrawal for the 62 patients who initiated therapy in Phase I were as follows: adverse events (2), non-compliance to protocol (22), withdrew consent (12), unknown (26). Of the 133 patients completing Phase I, 126 (94.7%) participated in Phase II suf ciently for intention to treat analysis, 105 (79.3%) completing the full Phase II protocol. Results are detailed in Table 2. Differential analysis of active vs placebo by underlying aetiology demonstrated no statistical difference in ef cacy of either VIP=P-1 or VIP=P-2. Patients recorded the erection duration; however, this included for many patients the period between onset of tumescence and detumescence, consequently some apparently long durations of erections were recorded. The median duration of erection for Phase I and II are as follows: Phase IÐVIP=P-1: 50 min, placebo 30 min; VIP=P-2: 30 min, placebo 15 min; and Phase IIÐVIP=P-1: 60 min, placebo 45 min; VIP=P-2: 40 min, placebo: 27.5 min. There were only two episodes of priapism throughout all phases of the study and these are described with adverse events below.
4 94 Table 2 Protocol and intention to treat ef cacy analysis Grade III responses Signi cance of difference Drug Study phase patients Active Placebo Active (%) Placebo (%) between active and placebo a Protocol analysis VIP=P (73.5%) 27 (12.7%) P < (77.2%) 18 (11.3%) P < Overall (75.1%) 45 (12.1%) P < VIP=P (62.0%) 4 (9.5%) P < (72.3%) 4 (11.1%) P < Overall (6.5%) 8 (10.3%) P < Intention to treat analysis VIP=P (72.2%) 31 (13.1%) P < (75.0%) 24(12.6%) P < Overall (73.7%) 55 (12.9) P < VIP=P (65.3%) 11 (15.9%) P < (75.0%) 5 (10.6%) P < Overall (69.1%) 16 (13.7%) P < a Wilcoxon signed rank test (95% CI). Overall satisfaction with the drug and the autoinjector was assessed by patients by means of a follow-up questionnaire. Patients and their partners completed a similar questionnaire on quality of life, these results are shown on Table 3. Overall, 85% or more of patients were satis ed or very satis ed with the drug and greater than 95% with the auto-injector. Over 81% of patients and 76% of their partners stated that their lives had been improved or greatly improved by the treatment. Adverse events During the Dose Assessment Phase, 80 of the 304 patients (27.3%) reported a total of 176 adverse events, the majority of which were categorized as mild to moderate. Related events included dizziness (7), headache (7), tachycardia=palpitations (14), ushing (24), bruising (13), bleeding at injection site (9), and priapism (1). Seven patients withdrew from further study due to the following adverse events: ushing (1), ushing and palpitations (2), palpitations (3), dizziness (1), and priapism (1). The onset of tumescence in the patient who developed priapism was 4 h after in clinic injection and responded to simple aspiration. During the Placebo Controlled Phase a total of 3267 injections for which diary entries were completed in 172 patients were analyzed for adverse events, these being summarized in Table 4. The major adverse event was facial ushing calculated per patient or injection, respectively, as follows: VIP=P %, 33.8%; VIP=P %, 33.9%, placebo 13.1%, 6.9%. The majority of patients described this as mild and transient and resulted in no patients withdrawing from this phase of the study. Urethral bleeding (usually characterized by a drop of blood at the meatus) was noted in 1.5%, 1.1% and 1.0% for VIP=P-1, VI:P=P-2 and placebo, Table 3 Patient and partner satisfaction results Responder respondents Score Assessment Patient Partner Phase eligible % % Description Satisfaction with drug X 1 133= Satis ed or very satis ed X 2 105= Satis ed or very satis ed Satisfaction with auto-injector X 1 146= Satis ed or very satis ed X 2 111= Satis ed or very satis ed Quality of life X 1 147= Improved or greatly improved X 1 114= Improved or greatly improved X 1 138= Improved or greatly improved X 2 108= Improved or greatly improved X refers to the responder.
5 Table 4 Related adverse events in placebo controlled phase 95 VIP=P-1 VIP=P-2 Placebo Patients % by Patients % by Patients % by Total number of injections and patients Local Bruising % % % Bleeding at % % % injection site Pain on % % % injection Pain post 0 0.% % % injection Urethral % % % bleeding Priapism % % % Systemic Flushing % % % Dizziness % % % Headache % % % Palpitation % % % Tachycardia % % % respectively. However, when comparing both Placebo Controlled Phases, the overall incidence of urethral bleeding fell from 1.8% in Phase I to 0.9% in Phase 2, suggesting a learning curve in self injection therapy. Only two patients withdrew because of an adverse event; death (1) and priapism (1). The patient who developed priapism had a similar episode following previous IC papaverine (60mg) therapy and responded to aspiration. The single death occurred 10 d after the last injection in a 70 y old with a history of two previous myocardial infarctions. One additional 65 y old patient with diabetes and hypertension suffered an acute myocardial infarction two months after his last injection of VIP=P. Discussion The role of intracavernosal administration of vasoactive compounds in the treatment of male ED has been well recognized. Papaverine, phentolamine and alprostadil, used alone, or in various combinations, have met with varying success rates, but have been accompanied with undesirable adverse effects, primarily priapism, brosis, and post-injection pain, the latter being particularly associated with alprostadil. 9 Although in earlier studies VIP used alone was only associated with tumescence when accompanied by visual or vibratory stimulation, 6 Gerstenberg et al 8 reported encouraging results in 52 patients utilizing 1380 self-injections of 30 mg VIP combined with 0.5 ± 2.0 mg phentolamine. All patients reported achieving an erection suf cient for intercourse, and there was no reported priapism, brosis, pain, or serious complications, though these authors subsequently observed that the 0.5 mg phentolamine combination was largely ineffective. These ndings were reinforced by McMahon's 10 recent report on the treatment of 20 men with ED utilizing VIP=P-1 and VIP=P-2 supplied in ampoules, in which he observed an overall ef cacy of 80% and a low side effect pro le (15% facial ushing, 10% injection pain). The auto-injector used in this study was designed to improve patient acceptance of self-injection as well as safety. The needle is not visible prior to injection therefore reducing patient anxiety. The pre- lled, single dose eliminates the need for reconstitution which requires a degree of dexterity and visual acuity that can challenge the diabetic and older individuals, as well as eliminating dosing errors and contamination from improper reconstitution. Intentional re-injection would be required for potential overdosing. The injection is virtually painless due to the small needle size and injection rate. Injection of the medication does not commence until needle depth has been reached, reducing the possibility of subcutaneous injection, the auto-injector is disposable and not reusable. This current study was designed in two phases: the dose assessment phase mimics clinical practice, in which an attempt is made to rule-out psychogenic, concomitant medication and hormonal imbalance aetiologies, prior to initiating appropriate
6 96 therapy and dosing determination. The cumulative response rates by aetiology of 80.6% in arteriogenic, 85.5% in diabetic, 100% in neurogenic, and 82.2% in mixed clearly attest to the ef cacy of VIP=P-1 and VIP=P-2. In addition, 82.0% of patients withdrawing from previous therapies responded, including a response rate of 81.1% from previous IC alprostadil, 82.2% from previous IC papaverine=phentolamine, and 73.2% of those who had withdrawn because of poor ef cacy. Whether analyzed per protocol or intention to treat, there was powerfully signi cant difference (P<0.001) between active and placebo when examining separately both VIP=P-1 and VIP=P-2. In the per protocol analysis of VIP=P-1 and VIP=P-2, active injections produced an erection suitable for intercourse in 75.1% and 66.5% respectively, with corresponding placebo responses of 12.2% and 10.3%. In the intention to treat analysis of VIP=P-1 and VIP=P-2, active injections produced an erection suitable for intercourse in 73.7% and 69.1% respectively, with corresponding placebo responses of 12.9% and 13.7%. The placebo response is remarkably low and clearly re ects the avoidance of overtly psychogenic patients in this study. There was little remarkable about the adverse event pro le. Although the majority of patients (74.4%) in the Placebo Controlled Phase noted mild transient ushing, the incidence per injection decreased to 33.8% and this resulted in no patients having withdrawn from this phase of the study. In 3 out of 304 patients (1.0%) in the Dose Assessment Phase facial ushing contributed to withdrawal, whereas the overall incidence of ushing was 7.9%. Transient ushing, per se, is not an uncommon feature of injection therapy, but was particularly prevalent in this study by virtue of the forward nature of the questions asked to record adverse occurrences for each administered injection. In view of the vasodilatory properties of the test medication and the high incidence of cardiovascular disorders in the patient population, the frequency of other cardiovascular related events (dizziness, tachycardia and palpitations) was exceptionally low, other events were uncommon. Minor urethral bleeding was noted following 1.4% of active injections and 1.0% of placebos and is possibly related to injection technique. There were two episodes of priapism in 304 patients, the incidence per injection in the Placebo Controlled Phase being 0.05%. Of signi cance no patient complained of post-injection pain throughout the entire study and no brosis was noted. The incidence of these observations was surprisingly low in view of the higher frequencies reported in other studies involving alternative pharmacotherapy. 9 Withdrawals from this study were consistent with those reported elsewhere. 9 Only 16.1% withdrew because of treatment failure and 2.9% patients due to adverse events. The 28.8% rate of non compliance in Placebo Controlled Phase was indicative of the demands of the study protocol. Conclusion This study unequivocally demonstrates the ef cacy and safety of the VIP=phentolamine combination (INVICORP TM ) in the treatment of non-psychogenic ED. There was no evidence of tachyphylaxis when comparing the ef cacy in the two Placebo Controlled Phases, for an overall period of 12 months. Both patient and partner satisfaction were remarkably high with a clear improvement in overall quality of life. Acknowledgements We wish to acknowledge the contribution made to this study by the following additional investigators: Mr MC Foster, Consultant Urologist, Good Hope Hospital, Sutton Cold eld, UK; Mr C Charig, Consultant Urologist, Epsom General Hospital, Epsom, UK; Mr M Hughes, Director of Urology, The Queen Elizabeth Hospital, Birmingham, UK; and Mr C Chapple, Urology Department, The Hallamshire Hospital, Shef eld, UK and nancial support from Senetek plc. References 1 Ottesen B, Wagner G, Virag R, Fahrenkrug J. Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br Med J 1984; 228: 9 ± Gu J et al. Decrease of vasoactive intestinal polypeptide (VIP) in the penises from impotent men. Lancet 1984; 315 ± Ehmke H, Junemann KP, Mayer B, Kummer W. Nitric oxide synthesis and vasoactive polypeptide colocalization in neurons innervating the human penile circulation. Int J Impot Res 1995; 7: 147 ± Fahrenkrug J. VIP and autonomic neurotransmission. Pharmacol Ther 1989; 41: Juneman KP et al. The role of vasoactive intestinal polypeptide as a neurotransmitter in canine penile erections: A combined in vivo and immunohistochemical study. J Urol 1987; 138: 871 ± Wagner G, Gerstenberg C. Intracavernosal injection of vasoactive intestinal polypeptide (VIP) does not induce erection in man per se. World J Urol 1987; 5: Roy JB, Petrone RL, Said SI. A clinical trial of vasoactive intestinal peptide to induce penile erection. J Urol 1990; 143: 302 ± Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J. Intracavernous self-injection with vasoactive intestinal polypeptide and phenotolamine in the management of erectile dysfunction. J Urol 1992; 147: 1277 ± Manning M, Junemann KP. Pharmacotherapy of erectile dysfunction. In: Hellstrom, WJG, ed. Male Infertility and Sexual Dysfunction. Springer-Verlag: New York, 1997, pp 440 ± 451.
7 10 McMahon CG. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impot Res 1996; 8: 233 ± Gerstenberg TC. A novel auto-injector for the administration of vasopotinða new treatment for erectile dysfunction Int J Impot Res 1995; 7: S
aviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB
aviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB 10 November 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationA dose-response study of alprostadil sterile powder (S.Po.) (Caverject # ) for the treatment of erectile dysfunction in Korean and Indonesian men
International Journal of Impotence Research (1997) 9, 47±51 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 A dose-response study of alprostadil sterile powder (S.Po.) (Caverject # ) for
More informationEvidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction
Evidence Review for Surrey Prescribing Clinical Network Treatment: Oral and non-oral combination therapy for erectile dysfunction Prepared by: Linda Honey Topic Submitted by: Prescribing Clinical Network
More informationErectile Dysfunction Medical Treatment
1 Erectile Dysfunction Medical Treatment Alireza Ghoreifi Assistant of Urology Mashhad University of Medical Sciences March 2012 2 Treatment of ED Unknown cases of ED First-line therapy Second-line therapy
More informationIntroduction. CG McMahon 1 * and K Touma 1
Predictive value of patient history and correlation of nocturnal penile tumescence, colour duplex Doppler ultrasonography and dynamic cavernosometry and cavernosography in the evaluation of erectile dysfunction
More informationOnset and duration of action of sildena l citrate for the treatment of erectile dysfunction
Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Ian Eardley, 1 Peter Ellis, 2 Mitradev Boolell 2 & Maria Wulff 2 1 Department of Urology, St James University
More information6.2 Elements for a Public Summary
6.2 Elements for a Public Summary 6.2.1 Overview of disease epidemiology Invicorp is to be used for erectile dysfunction, also known as impotence, the inability to get and maintain an erection that is
More informationOral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction
(2000) 12, Suppl 1, S75±S80 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of
More informationCanadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction
Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Last reviewed July 2014 Objectives 1. Define erectile dysfunction 2. List and classify the risk factors for erectile dysfunction
More informationErectile Dysfunction: A Primer for Primary Care Providers
Erectile Dysfunction: A Primer for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the definition, incidence and prevalence of Erectile Dysfunction in the U.S. 2. Understand
More informationIntracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men
(2001) 13, 317 321 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic
More informationMALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
MALE SEXUAL DYSFUNCTION Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara DEFINITION The inability to achieve a satisfactory sexual relationship May involve : - inadequacy
More informationIntracavernous administration of SIN-1 þ VIP in an in vivo rabbit model for erectile function
(2002) 14, 44 49 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Intracavernous administration of SIN-1 þ VIP in an in vivo rabbit model for erectile function
More information, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001
Erectile Dysfunction David Stultz, MD September 10, 2001 Case Presentation A 66 year old male presents to your office requesting Viagra. He states that for the past year he has had difficulty forming
More informationManaging Erectile Dysfunction
Managing Erectile Dysfunction Lewis E. Harpster MD, FACS Urology of Central PA 4/23/16 1 Objectives 1. Review physiologic mechanism of erection 2. Discuss medical management of ED 3. Discuss surgical management
More informationManaging the Patient with Erectile Dysfunction: What Would You Do?
Managing the Patient with Erectile Dysfunction: What Would You Do? Florida A & M University College of Pharmacy and Pharmaceutical Sciences 42 nd Annual Clinical Symposium Wayne A. Sampson, M.D. Cross
More informationED treatments: PDE5 inhibitors, injections and vacuum devices
ED treatments: PDE5 inhibitors, injections and vacuum devices Martin Steggall Clinical Nurse Specialist (Erectile Dysfunction and Premature Ejaculation) Barts Health NHS Trust; Associate Dean, Director
More informationPriapism. Medical Student case-based learning
Priapism Medical Student case-based learning A 45 year old man presents with an erection lasting over 5 hours. What are the two major subtypes of priapism? Types of Priapism Ischemic veno-occlusive or
More informationErectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid
Erectile dysfunction By Anas Hindawi Supervised by Dr Khalid AL Sayyid ED is the persistent/recurrent inability to attain and/or maintain a penile erection rigid enough for satisfactory sexual intercourse
More informationGUIDELINES ON ERECTILE DYSFUNCTION
GUIDELINES ON ERECTILE DYSFUNCTION (Text updated March 2005) E. Wespes (chairman), E. Amar, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi, J. Pryor, Y. Vardi 88 Erectile Dysfunction Eur Urol 2001;40:97-101
More informationIC351 (tadalafil, Cialis): update on clinical experience
(2002) 14, Suppl 1, S57 S64 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir IC351 (tadalafil, Cialis): update on clinical experience 1 * 1 Urological practice,
More informationORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction
Sildenafil for Male Erectile Dysfunction A Systematic Review and Meta-analysis ORIGINAL INVESTIGATION Howard A. Fink, MD, MPH; Roderick Mac Donald, MS; Indulis R. Rutks, BS; David B. Nelson, PhD; Timothy
More informationIntroduction. H Porst
International Journal of Impotence Research (1997) 9, 187±192 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 (medicated urethral system for erection) vs intracavernous AlprostadilÐa comparative
More informationGUIDELINES ON ERECTILE DYSFUNCTION
16 GUIDELINES ON ERECTILE DYSFUNCTION E. Wespes (chairman), E. Amar, D. Hatzichristou, Dr. F. Montorsi, J. Pryor, Y. Vardi Eur Urol 2002;41:1-5 1. Background, definition and classification Male erectile
More informationClinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction
Medicine Update (2004): 11(9), 47-51 Clinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction Dr. Roumen Bostandjiev, Ph.D. Founder and Director of Sexology
More informationCitation 泌尿器科紀要 (1988), 34(7):
Title Can an intracavernous papaverine in arteriogenic impotence? Author(s) Imagawa, Akio; Kawanishi, Yasuo Citation 泌尿器科紀要 (1988), 34(7): 1185-1189 Issue Date 1988-07 URL http://hdl.handle.net/2433/119644
More informationERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204)
ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION Gregory Harochaw Pharmacy Manager Tache Pharmacy (204) 233-3469 Nerve Function After careful prostatectomy where the erectile
More informationDisclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION
ASSESSMENT OF ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital North St Specialist Suites Mater Hospital 3 rd Floor Mater Private Clinic Wesley Hospital Suite 5 Level 9 Evan Thomson Bld Cleveland-
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationINTRACAVERNOSAL INJECTION OF PHARMACOLOGICAL AGENTS IN THE DIAGNOSIS AND TREATMENT OF IMPOTENCE
INTRACAVERNOSAL INJECTION OF PHARMACOLOGICAL AGENTS IN THE DIAGNOSIS AND TREATMENT OF IMPOTENCE Abstract Pages with reference to book, From 172 To 176 Qaisar H Siraj ( Armed Forces Institute of Pathology,
More informationD Udelson, A Nehra, DG Hatzichristou, K Azadzoi, RB Moreland, RJ Krane, I Saenz de Tejada and I Goldstein
International Journal of Impotence Research (1998) 10, 89±99 ß 1998 Stockton Press All rights reserved 0955-9930/98 $12.00 http://www.stockton-press.co.uk/ijir Engineering analysis of penile hemodynamic
More informationASSESSMENT OF PREMATURE EJACULATION AND ERECTILE DYSFUNCTION
ASSESSMENT OF PREMATURE EJACULATION AND ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital Wickham Terrace Spring Hill Mater Private Clinic, South Brisbane Shore St West Medical Centre, Cleveland
More informationERECTILE DYSFUNCTION DIAGNOSIS
ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz
More informationIs there a role of radial rigidity in the evaluation of erectile dysfunction?
(2001) 13, 200±204 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Is there a role of radial rigidity in the evaluation of erectile dysfunction? JH Ku 1 *, YS
More informationDefined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several
Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several months and occurring at least half the time. Vinik
More informationLong-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis
(2003) 15, 318 322 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction
More informationSchemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i
Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i M. Lazzeri MD-PhD Department of Urology Ist. Clinico Humanitas IRCCS Schema
More informationAssessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation
(2001) 13, 41±45 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation
More information/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY
0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7
More informationA Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction
A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction Anthony J. Bella MD, FRCSC Division of Urology, Department of Surgery and Department of Neuroscience
More informationSpring balance evaluation of the ischiocavernosus muscle
International Journal of Impotence Research (2001) 13, 294 297 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Spring balance evaluation of the ischiocavernosus
More informationSexual Function for Men with Spinal Cord Injury
Sexual Function for Men with Spinal Cord Injury A spinal cord injury (SCI) affects a man's sexuality both physically and psychologically. The type and level of injury both can play a role on the impact
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationMODULE 4: ERECTILE DYSFUNCTION
MODULE 4: ERECTILE DYSFUNCTION KEYWORDS: Erectile dysfunction, phosphodiesterase inhibitors, sexual dysfunction LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to: 1.
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 199, by the Massachusetts Medical Society VOLUME 33 M AY 14, 199 NUMBER ORAL IN THE TREATMENT OF ERECTILE DYSFUNCTION IRWIN GOLDSTEIN, M.D., TOM F. LUE, M.D.,
More informationSexual impotence. the forgotten complication
Sexual impotence the forgotten complication CHECK YOURSELF YOUR SEXUAL PERFORMANCE 1. Have you had recently difficulties achieving a full erection? 2. Does it happens at least two out of four times trying
More informationThe anocavernosal erectile dysfunction syndrome II Anal ssure and erectile dysfunction
(2000) 12, 279±283 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir The anocavernosal erectile dysfunction syndrome II Anal ssure and erectile dysfunction A Sha
More informationLONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP
ADULT UROLOGY LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, RAKESH SHARMA, KUSH K. GOYAL, DROGO
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) April 2014 Review April 2017 Bulletin 197: Dapoxetine for Premature Ejaculation JPC Recommendations: To support the East of England Priorities Advisory
More informationGUIDELINES ON PRIAPISM
GUIDELINES ON PRIAPISM (Text update March 2015) A. Salonia, I. Eardley, F. Giuliano, I. Moncada, K. Hatzimouratidis Eur Urol 2014 Feb;65(2):480-9 Introduction Priapism is a pathological condition representing
More informationReview Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
Advances in Urology Volume 2009, Article ID 852437, 4 pages doi:10.1155/2009/852437 Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution
More informationfor ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology
Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly
More informationDifferent hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders
DOI: 10.1111/j.1745-7262.2007.00227.x www.asiaandro.com. Clinical Experience. Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders Shih-Tsung
More informationCurrent perspectives on intracavernosal pharmacotherapy for erectile dysfunction
(2000) 12, Suppl 4, S91±S100 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir for erectile dysfunction 1 * 1 Neuer Jungfernstieg 6a, 20354 Hamburg, Germany Thirty
More informationUnstable angina following intracavernous injection of alprostadil: a case study
1 di 6 03/09/2013 21.59 BMJ Case Rep. 2009; 2009: bcr03.2009.1658. Published online 2009 June 3. doi: 10.1136/bcr.03.2009.1658 Unexpected outcome (positive or negative) including adverse drug reactions
More informationThe effect of sildenafil on electrostimulation-induced erection in the rat model
(2002) 14, 251 255 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The effect of sildenafil on electrostimulation-induced erection in the rat model N Ueno 1,
More information/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY
0022-5347/02/1684-1332/0 Vol. 168, 1332 1336, October 2002 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2002 by AMERICAN UROLOGICAL ASSOCIATION, INC. DOI: 10.1097/01.ju.0000028041.27703.da Original
More informationMEDICAL POLICY SUBJECT: ERECTILE DYSFUNCTION. POLICY NUMBER: CATEGORY: Miscellaneous
MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationTHE FACTS ABOUT MEN S SEXUAL HEALTH
Come in and experience the Chesapeake Urology difference. Call 877-422-8237 to make an appointment with a urologist today or visit www.chesapeakeurology.com to learn more about our specialized care for
More informationReview of intraurethral suppositories and iontophoresis therapy for erectile dysfunction
(2000) 12, Suppl 4, S86±S90 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Review of intraurethral suppositories and iontophoresis therapy for erectile dysfunction
More informationKEYWORDS: Erectile dysfunction, phosphodiesterase inhibitors, sexual dysfunction.
NATIONAL MEDICAL STUDENT CURRICULUM ERECTILE DYSFUNCTION (ED) This document was amended in July 2016 to reflect literature that was released since the original publication of this content in May 2012 and
More informationErectile Dysfunction Case Study 2. Medical Student Case-Based Learning
Erectile Dysfunction Case Study 2 Medical Student Case-Based Learning The Case of Mr. Power s Limp Mojo Mr. Powers develops erectile dysfunction after his radical prostatectomy for prostate cancer. You
More informationUp to 85 Percent of Men Achieved Significantly Improved Erections
Corporate Investor Relations First Release of Vardenafil Phase III Pivotal Study Data: Up to 85 Percent of Men Achieved Significantly Improved Erections Additional Phase III Data Show Significant Improvement
More informationHigh dose sildenafil citrate as a salvage therapy for severe erectile dysfunction
(2002) 14, 533 538 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction 1 * 1 Australian
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationSidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology
Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology (www.intbrazjurol.com.br) glinas@terra.com.br Conflict of Interest: In the
More informationReview Article Overview of Contemporary Penile Rehabilitation Therapies
Hindawi Publishing Corporation Advances in Urology Volume 2008, Article ID 481218, 6 pages doi:10.1155/2008/481218 Review Article Overview of Contemporary Penile Rehabilitation Therapies Peter Hinh and
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationGUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation
GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Text update March 2009) E. Wespes, E. Amar, I. Eardley, F. Giuliano, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi,
More informationEndocrine Diagnosis and Treatment
Endocrine Diagnosis and Treatment INTRACAVERNOSAL INJECTION THERAPY AND OTHER TREATMENT OPTIONS FOR ERECTILE DYSFUNCTION Natan Bar-Chama, M.D., Stanley Zaslau, M.D., and Michael Gribetz, M.D. ABSTRACT
More informationErectile Dysfunction; It s Not Just About Sex
Erectile Dysfunction; It s Not Just About Sex Disclosures Conflict of interest: I am not paid by Boston Scientific but once in a while they buy me a tasty meal. I do routinely use their products without
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2012 Review date: September 2014 Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy JPC Recommendation:
More informationSEXUAL RELATIONSHIPS AND FERTILITY FOLLOWING SPINAL CORD INJURY
NATIONAL SPINAL INJURIES CENTRE STOKE MANDEVILLE HOSPITAL A HANDOUT PREPARED FOR PATIENTS BY SPINAL OUTPATIENT SERVICES SEXUAL RELATIONSHIPS AND FERTILITY FOLLOWING SPINAL CORD INJURY Mary Leonard, RGN.
More informationManagement of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction
Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Robert C. Eyre, MD, FACS Associate Clinical Professor of Surgery (Urology) Harvard Medical School Post-prostatectomy Incontinence
More informationERECTILE DYSFUNCTION TREATMENTS
ERECTILE DYSFUNCTION TREATMENTS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationPenile rehabilitation after radical prostatectomy: patients attitude and feasibility in China
Original Article Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China Yi-Jun Shen 1,2, Jian Li 1,2, Ding-Wei Ye 1,2 1 Department of Urology, Fudan University Shanghai
More informationProduct Introduction
Product Introduction 康達生命科學有限公司 Contek Life Science Co., Ltd. Red Algae Peptide Hydrolysate-EDpeptide The Next Generations of Erectile Dysfunction Cure Introduction of small peptides Erectile dysfunction
More informationAbout Erectile Dysfunction. Causes, self-test and treatment
About Erectile Dysfunction Causes, self-test and treatment 2015 One Way S.r.l. All rights reserved. Gift copy for physicians. Illustrated by Davide Ceccon With an unrestricted grant from Recordati About
More informationTestosterone and PDE5 inhibitors in the aging male
Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More information** REGULATORY ALERT **
Complete Summary GUIDELINE TITLE The management of erectile dysfunction: an update. BIBLIOGRAPHIC SOURCE(S) Erectile Dysfunction Guideline Update Panel. The management of erectile dysfunction: an update.
More informationPHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker
PACKAGE INSERT Pr PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker ACTIONS AND CLINICAL PHARMACOLOGY Phentolamine produces an alpha-adrenergic
More informationRecovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil
Sexual Medicine RECOVERY OF ERECTILE FUNCTION AFTER NERVE-SPARING RP WITH NIGHTLY LOW-DOSE SILDENAFIL BANNOWSKY et al. Associate Editor Michael G. Wyllie Editorial Board Ian Eardley, UK Jean Fourcroy,
More informationMANAGEMENT UPDATE , LLC MedReviews
MANAGEMENT UPDATE 2013 MedReviews, LLC rostate cancer is the most common cancer in men over the age of 50 years. 1 When patients undergo a radical prostatectomy (RP), there is a risk of postoperative erectile
More informationDiagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist
Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia
More informationWITH ERECTILE DYSFUNCTION
Clinical Urology International Braz J Urol Vol. 29 (4): 320-326, July - August, 2003 Official Journal of the Brazilian Society of Urology OF PATIENTS WITH ERECTILE DYSFUNCTION JOAQUIM A. CLARO, SÉRGIO
More informationIan Eardley Department of Urology, Leeds Teaching Hospital Trust
Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter
More informationPhysiology and disturbances of sexual functions Prof. Jolanta Słowikowska-Hilczer, M.D., Ph.D.
Physiology and disturbances of sexual functions Prof. Jolanta Słowikowska-Hilczer, M.D., Ph.D. Department of Andrology and Reproductive Endocrinology Medical University of Łódź, Poland SEXUALITY Sexuality
More informationClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Sanofi-Aventis ClinicalTrials.gov
More informationInitial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study
International Journal of Impotence Research (2014), 1 5 2014 Macmillan Publishers Limited All rights reserved 0955-9930/14 www.nature.com/ijir ORIGINAL ARTICLE Initial experience with linear focused shockwave
More informationErectile dysfunction Simply explained
Ratgeber Erektionsstörungen Englisch... Erectile dysfunction Simply explained The Guide Contents Foreword 04 Erectile dysfunction Simply understood 05 Causes of erectile dysfunction 07 Treatment options
More informationQuestions & Answers about Sexuality and Intimacy after Bladder Cancer. Part III: Causes and Treatments for Sexual Dysfunction
Questions & Answers about Sexuality and Intimacy after Bladder Cancer A Valentine's chat with Dr. Trinity Bivalacqua Monday, February 13, 2017 Part III: Causes and Treatments for Sexual Dysfunction Presented
More informationTreatment of male sexual dysfunction
Simon Holmes Department of Urology, St Mary's Hospital, Portsmouth, UK Male sexual dysfunction is a prevalent condition in the population, is a major health problem and has previously been both under diagnosed
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationPatient Information ERECTILE DYSFUNCTION. Department of Urology
ERECTILE DYSFUNCTION What is erectile dysfunction? Erectile dysfunction (impotence) is the inability to get or keep an erection sufficient for sexual intercourse. One in ten men (10%) suffer from impotence
More informationClinical Commissioning Policy Proposition:
Clinical Commissioning Policy Proposition: Penile prosthesis surgery for end stage erectile dysfunction Version Number: NHS England B14X10/01 Information Reader Box (IRB) to be inserted on inside front
More informationErectile Dysfunction (ED) or Impotence
Erectile Dysfunction (ED) or Impotence Introduction Impotence is a consistent inability to sustain an erection sufficient for sexual intercourse. Medical professionals often use the term "erectile dysfunction"
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationErectile Dysfunction and the Prostate Cancer Patient
BAUN & Prostate cancer UK Erectile Dysfunction Study Day Erectile Dysfunction and the Prostate Cancer Patient Lorraine Montgomery Specialist Nurse Practitioner Urology Queen Elizabeth Hospital Gateshead
More information